US Patent

US11944611 — Capsid inhibitors for the treatment of HIV

Method of Use · Assigned to Gilead Sciences Inc · Expires 2041-08-28 · 15y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects the use of compounds of Formula (Ia) and (Ib) for treating HIV infections in patients with multidrug-resistant HIV.

USPTO Abstract

The present disclosure relates to compounds of Formula (Ia) and (Ib): or a pharmaceutically acceptable salt thereof, which are useful in the treatment of an HIV infection in heavily treatment-experienced patients with multidrug resistant HIV infection.

Drugs covered by this patent

lenacapavir-sodium (LENACAPAVIR SODIUM)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3507`	—	lenacapavir-sodium
`U-3507`	—	lenacapavir-sodium

Patent Metadata

Patent number: US11944611
Jurisdiction: US
Classification: Method of Use
Expires: 2041-08-28
Drug substance claim: No
Drug product claim: No
Assignee: Gilead Sciences Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.